Metformin in cancer therapy: a new perspective for an old antidiabetic drug?

Area of Science:

• Oncology
• Pharmacology
• Metabolic Diseases

Background:

• Metformin is a widely prescribed antidiabetic medication.
• Emerging evidence suggests metformin possesses anticancer properties.
• Cancer incidence reduction is observed in patients using metformin.

Purpose of the Study:

• To review the evidence supporting metformin's efficacy as an anticancer drug.
• To explore the mechanisms underlying metformin's potential antitumoral effects.

Main Methods:

• Review of epidemiological studies on metformin and cancer incidence.
• Analysis of research on metformin's effects on insulin resistance and insulin levels.
• Examination of studies detailing metformin's direct impact on cancer cell growth.
• Investigation of metformin's role in activating the AMP-activated protein kinase (AMPK) pathway.

Main Results:

• Epidemiological data suggest a lower incidence of cancer in metformin users.
• Metformin reduces insulin resistance, thereby lowering insulin levels, which can inhibit cancer cell proliferation.
• Direct inhibitory effects of metformin on cancer cell growth and tumor development have been reported.
• Metformin activates the AMPK pathway, a key cellular energy sensor implicated in cancer regulation.

Conclusions:

• Metformin exhibits multifaceted anticancer potential through various biological mechanisms.
• Its effects on insulin regulation and direct cytotoxicity make it a promising candidate for cancer therapy.
• Activation of the AMPK pathway by metformin offers a potential therapeutic target for cancer treatment.